We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Amoxapine as an Atypical Antipsychotic: A Comparative Study Vs Risperidone.
- Authors
Apiquian, Rogelio; Fresan, Ana; Ulloa, Rosa-Elena; de la Fuente-Sandoval, Camilo; Herrera-Estrella, Miguel; Vazquez, Alejandra; Nicolini, Humberto; Kapur, Shitij
- Abstract
Amoxapine is marketed as an antidepressant. However, its invitro profile, receptor occupancy and preclinical effects are very similar to atypical antipsychotics. Amoxapine has also shown efficacy as an atypical antipsychotic in open trials. The objective of this study was to compare the antipsychotic and side effect profile of amoxapine and risperidone in a randomised assignment, standardized dosing, double-blind trial of acutely psychotic patients with schizophrenia. A total of 48 schizophrenic patients were enrolled and randomized in a double-blind 6-week trial to receive either risperidone (up to 5 mg/day) or amoxapine (up to 250 mg/day). Positive, negative, affective symptoms and motor side effects were measured using standardized weekly assessments. Prolactin levels were also determined at baseline and at the end of the study. A total of 39 patients (amoxapine, n=22; risperidone, n=21) completed the trial. Both pharmacological treatments, amoxapine 228.0 mg/day (SD=34.6) and risperidone 4.5 mg/day (SD=0.7), showed equivalent improvement in positive, negative, and depressive symptoms. Amoxapine was associated with less EPS and less prolactin elevation than risperidone. These data support previous reports about the efficacy of amoxapine as an atypical antipsychotic. Since amoxapine is off-patent, it may be a valuable low-cost alternative to new atypical antipsychotics, particularly in low-income countries where the majority of the patients are still treated with typical antipsychotics.Neuropsychopharmacology (2005) 30, 2236–2244. doi:10.1038/sj.npp.1300796; published online 8 June 2005
- Subjects
ANTIPSYCHOTIC agents; PHARMACODYNAMICS; MENTAL depression; ANTIDEPRESSANTS; DRUG therapy for psychoses; RISPERIDONE; DEPRESSED persons; NEUROPSYCHOPHARMACOLOGY
- Publication
Neuropsychopharmacology, 2005, Vol 30, Issue 12, p2236
- ISSN
0893-133X
- Publication type
Article
- DOI
10.1038/sj.npp.1300796